Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;26(1):89-103.
doi: 10.1007/s40291-021-00567-x. Epub 2021 Dec 14.

Molecular Genetic Techniques in Biomarker Analysis Relevant for Drugs Centrally Approved in Europe

Tatjana Huebner  1 , Michael Steffens  2 , Catharina Scholl  2
Affiliations
Review

Molecular Genetic Techniques in Biomarker Analysis Relevant for Drugs Centrally Approved in Europe

Tatjana Huebner et al. Mol Diagn Ther. 2022 Jan.

Abstract

On the basis of scientific evidence, information on the option, recommendation or requirement to test for pharmacogenetic or pharmacogenomic biomarkers is incorporated in the Summary of Product Characteristics of an increasing number of drugs in Europe. A screening of the Genetic Testing Registry (GTR) showed that a variety of molecular genetic testing methods is currently offered worldwide in testing services with regard to according drugs and biomarkers. Thereby, among the methodology indicated in the screened GTR category 'Molecular Genetics', next-generation sequencing is applied for identification of the largest proportion of evaluated biomarkers that are relevant for therapeutic management of centrally approved drugs in Europe. However, sufficient information on regulatory clearances, clinical utility, analytical and clinical validity of applied methods is rarely provided.

PubMed Disclaimer

Conflict of interest statement

The authors declare that research for this review article was performed without commercial or financial interests.

References

    1. Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics. 2014;11(4):699–707. doi: 10.1007/s13311-014-0288-8. - DOI - PMC - PubMed
    1. Shimazawa R, Ikeda M. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan. J Clin Pharm Ther. 2013;38(6):468–475. doi: 10.1111/jcpt.12089. - DOI - PubMed
    1. EUR-Lex. Regulation (EU) 2017/746 of the European Parliament and of the COUNCIL: EUR-Lex; 2020. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32017R0746. Accessed 04 Mar 2021.
    1. EMA. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. In: (CHMP) CfMPfHU, editor. EMA; 2011.
    1. PharmGKB. Drug Label Annotations: PharmGKB; 2020. https://www.pharmgkb.org/labelAnnotations. Accessed 25 Aug 2020.

Publication types

LinkOut - more resources